You are here:
26 July 2018 / deal

Acquisition of Takeda Chromo by Shanghai Pharmaceuticals Holding Co.

Loyens & Loeff advised Shanghai Pharmaceuticals on the acquisition of Takeda Chromo Beteiligungs AG.

The Belgian ‘Cayman tax’ and its impact on wealth and estate planning in Belgium

Shanghai Pharmaceuticals Holding Co. (Hong Kong) announced the entering into a share purchase agreement with Takeda AG, a wholly-owned subsidiary of Takeda Japan (listed on the Tokyo Stock Exchange) to acquire 100% of the issued and outstanding share capital of Takeda Chromo Beteiligungs AG. Upon completion of the USD 144 million acquisition, Shanghai Pharmaceuticals will increase its direct and indirect shareholding in Techpool Bio-pharma Co., Ltd, a global leader in natural urine protein drugs, to approximately 67,14%. The acquisition is, among other conditions, still subject to approval by the China National Market Supervision Administration.

Loyens & Loeff advised Shanghai Pharmaceuticals Holding Co. as Swiss transaction counsel on this acquisition. The team was led by partner Marco Toni (Corporate / M&A, Switzerland) and consisted of Jana Bieli (Corporate / M&A, Switzerland) and Rebecca Kühne (Tax, Switzerland).

 



Swiss Corporate Tax Reform adopted

The Swiss parliament adopted the bill for the Swiss corporate tax reform package, the Tax Proposal 17. Learn more how to get ready for TP 17. read more
Employment tax

Loyens & Loeff advised Kongsberg Actuation Systems B.V.

L&L advised Kongsberg Actuation Systems B.V. on the issuance of EUR 275,000,000 5.000% Senior Secured Notes due 2025. read more

New FinTech License – What will be the Requirements?

The Swiss Federal Department of Finance initiated a consultation regarding a newly created FinTech license. What are the requirements? read more